Loading

Ziphius LLC

June 16, 2025
Company Presentation
Infectious Disease and Vaccines
Ziphius, a Belgium/US-based private biotech company, is advancing a next-generation platform utilizing self-amplifying RNA (saRNA) and lipid nanoparticles (LNPs) to develop first and best in class medicines for infectious diseases, rare diseases, and oncology. Since our founding in 2019, we have raised $43M and are now preparing to secure an additional $50M in 2025 to accelerate the development of our programs and reach our first clinical milestones. With a dedicated team of 65 professionals based in Belgium and the US (New York), Ziphius is committed to developing first- and best-in-class RNA medicines. Pipeline: 1. Chlamydia Trachomatis vaccine 2. Pan-Corona vaccine 3. Cystic Fibrosis therapy Milestones Recent preclinical studies data in Pigs: -Superior Humoral and CMI responses -Ongoing NHP studies
Ziphius LLC
Company HQ City: New York
Company HQ State: NY
Company HQ Country: United States
Year Founded: 2019
Lead Product in Development: Chlamydia Trachomatis Vaccine Pancorona Vaccine Cystic fibrosis therapy

CEO

Chris Cardon - CEO

Year Founded

2019

Development Phase of Lead Product

Pre-Clinical

Number of Unlicensed Products Looking for Licensing

-

When you expect your next catalyst update?

Non Human Primates study result

What is your next catalyst (value inflection) update?

March, 2025

Website

https://ziphius.org/
Primary Speaker
Damien Dessis
Damien Dessis
Chief Business Ofiicer
Ziphius LLC

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS